Current Drug Safety
Title: Editorial [Hot Topic: When Can a Drug be Declared “Safe”? (Guest Editors: Frank M.C. Besag & Seetal Dodd)]
Volume: 5 Issue: 2
Author(s): Frank M.C. Besag and Seetal Dodd
Affiliation:
Export Options
About this article
Cite this article as:
Besag M.C. Frank and Dodd Seetal, Editorial [Hot Topic: When Can a Drug be Declared “Safe”? (Guest Editors: Frank M.C. Besag & Seetal Dodd)], Current Drug Safety 2010; 5 (2) . https://dx.doi.org/10.2174/157488610790936141
DOI https://dx.doi.org/10.2174/157488610790936141 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
26
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Raf Inhibitors as Therapeutic Agents Against Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Targeting Pain-evoking Transient Receptor Potential Channels for the Treatment of Pain
Current Neuropharmacology Specific Roles of NMDA Receptor Subunits in Mental Disorders
Current Molecular Medicine Conference Report: Summary Report of the International Association of Neurorestoratology VII Conference: Regulations, Ethics, Science, and the Need of Patients Care in Neurorestoratology
CNS & Neurological Disorders - Drug Targets Conotoxins: Structure, Therapeutic Potential and Pharmacological Applications
Current Pharmaceutical Design Synthesis and Studies on Anticonvulsant and Antibacterial Activities of 1- Alkyl-4-(4H-1,2,4-triazol-4-yl)piperidine Derivatives
Letters in Drug Design & Discovery Current Quest in Natural Bioactive Compounds for Alzheimer’s Disease: Multi-Targeted-Designed-Ligand Based Approach with Preclinical and Clinical Based Evidence
Current Drug Targets Patented Small Molecules Used for Reprogramming
Recent Patents on Regenerative Medicine Molecular Mechanisms of Cytochrome P450 Induction: Potential for Drug-Drug Interactions
Current Protein & Peptide Science Phytochemicals: Potential in Management of Climacteric Neurobiology
Current Pharmaceutical Design Synthesis and Anticonvulsant Activity of α-Amino Acid Amide Derivatives
Current Bioactive Compounds CB1 Cannabinoid Receptors and their Associated Proteins
Current Medicinal Chemistry Huntingtons Disease: The Value of Transcranial Meganetic Stimulation
Current Medicinal Chemistry Disorder in Milk Proteins: α-Lactalbumin. Part B. A Multifunctional Whey Protein Acting as an Oligomeric Molten Globular “Oil Container” in the Anti-Tumorigenic Drugs, Liprotides
Current Protein & Peptide Science Inflammation and Epilepsy: Preclinical Findings and Potential Clinical Translation
Current Pharmaceutical Design New Insights in Prolactin Releasing Peptide (Prrp) in the Brain
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Gap Junctions as Therapeutic Targets in Brain Injury Following Hypoxia- Ischemia
Recent Patents on CNS Drug Discovery (Discontinued) The Urokinase Receptor Interactome
Current Pharmaceutical Design Novel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome
Current Pharmaceutical Design Human Endometrial and Ovarian Cancer Cells: Histone Deacetylase Inhibitors Exhibit Antiproliferative Activity, Potently Induce Cell Cycle Arrest, and Stimulate Apoptosis
Current Medicinal Chemistry